Travaux scientifiques

Prof. Dr. Özge Gümüşay

69 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil
  1. Comparison of three different concurrent chemoradiation regimens for treatment of laryngeal cancer

    European Archives of Oto-Rhino-Laryngology, 2015

    DOI 10.1007/s00405-015-3854-8 PMID 26683470 4 citations (Europe PMC) Source : OpenAlex

  2. Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients

    Wiener klinische Wochenschrift, 2015

    DOI 10.1007/s00508-015-0858-8 PMID 26373751 2 citations (Europe PMC) Source : OpenAlex

  3. Factors predicting the development of distant metastases in patients with head and neck squamous cell carcinoma: A retrospective study from a single centre.

    PubMed, 2015

    PMID 26011345 4 citations (Europe PMC) Source : OpenAlex

  4. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.3_suppl.25 Source : OpenAlex

  5. Salvage Chemotherapy with Weekly Paclitaxel for Metastatic Melanoma

    Asian Pacific Journal of Cancer Prevention, 2015

    DOI 10.7314/apjcp.2015.16.6.2581 PMID 25824800 Texte intégral en libre accèsSource : OpenAlex

  6. Akciğerin Primer Şeffaf Hücreli Şeker Tümörü: Bir Olgu Sunumu

    Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi, 2015

    Source : OpenAlex

  7. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-d-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin

    Annals of Nuclear Medicine, 2014

    DOI 10.1007/s12149-014-0896-8 PMID 25270711 2 citations (Europe PMC) Source : OpenAlex

  8. Factors predicting recurrence in patients with grade III glial tumors: impact of adjuvant temozolomide on recurrence.

    PubMed, 2014

    PMID 25536613 Source : OpenAlex

  9. Solitary Cerebral Metastases from Renal Cell Carcinoma 16 years After Nephrectomy

    Acta Oncologica Turcica, 2014

    DOI 10.5505/aot.2014.47966 Texte intégral en libre accèsSource : OpenAlex

  10. Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma

    International Urology and Nephrology, 2013

    DOI 10.1007/s11255-013-0613-x PMID 24307427 20 citations (Europe PMC) Source : OpenAlex

  11. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology

    Breast Cancer, 2013

    DOI 10.1007/s12282-013-0441-y PMID 23335064 20 citations (Europe PMC) Source : OpenAlex

  12. Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology

    Journal of Cancer Research and Clinical Oncology, 2013

    DOI 10.1007/s00432-013-1553-7 PMID 24292400 14 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  13. Diagnostic potential of serum direct markers and non‐invasive fibrosis models in patients with chronic hepatitis B

    Hepatology Research, 2012

    DOI 10.1111/j.1872-034x.2012.01057.x PMID 22734888 24 citations (Europe PMC) Source : OpenAlex

  14. Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology

    Asian Pacific Journal of Cancer Prevention, 2012

    DOI 10.7314/apjcp.2012.13.8.3973 PMID 23098502 19 citations (Europe PMC) Source : OpenAlex

  15. Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)

    Oncology, 2012

    DOI 10.1159/000338782 PMID 22814315 21 citations (Europe PMC) Source : OpenAlex

  16. Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study.

    Journal of Clinical Oncology, 2012

    DOI 10.1200/jco.2012.30.15_suppl.638 1 citation (OpenAlex) Source : OpenAlex

  17. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer

    Source : page de profil sur acibadem.com.tr

  18. Immunotherapy Toxicity: identification and management

    Source : page de profil sur acibadem.com.tr

  19. Pembrolizumab for Early Triple-Negative Breast Cancer

    Source : page de profil sur acibadem.com.tr